LIke ThisLIke ThisLIke This

Kimberly  Stegmaier, MD

kimberly stagmaier
Research Center:
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Medicine Research
Hematology/Oncology Research
Hospital Title:
Assistant in Medicine
Academic Title:
Assistant Professor of Pediatrics, Harvard Medical School
Research Focus Area:
Pediatric and other malignancies
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Kimberly Stegmaier’s laboratory champions the importance of cancer target and therapy discovery in academic centers for malignancies affecting children not likely to be pursued by the pharmaceutical industry. Her research program focuses on the integration of genomic, genetic, and proteomic approaches to identify new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. In particular, she developed a chemical genomic approach to drug screening, Gene Expression-based High-throughput Screening (GE-HTS), in which gene expression signatures serve as surrogates for different biological states. This is a generic method and a departure from traditional target-based or phenotype-based screening. Her laboratory has applied the GE-HTS approach to the alteration of the malignant state (i.e., induction of acute myeloid leukemia (AML) and neuroblastoma differentiation) and to the modulation of intractable protein targets such as transcription factor abnormalities in Ewing sarcoma and T-cell acute lymphoblastic leukemia. Compounds emerging from screening efforts have served as clinical leads for trial development as well as tool compounds for probing mechanism of oncogenesis and for the identification of new cancer targets. Ongoing work in the laboratory focuses on applying these approaches to:

  1. Identification of new cancer-promoting protein targets
  2. Modulation of pharmacologicaly challenging oncoproteins (e.g., transcription factors)
  3. Identification of new small-molecule inducers of cancer cell differentiation

The laboratory’s ultimate goal is the translation of compelling findings to clinical trial. Clinical trials for AML and Ewing sarcoma have resulted from this research.

About Kimberly Stegmaier

Kimberly Stegmaier is a physician-scientist who received an MD from Harvard Medical School. She completed her Pediatrics internship/residency at Children's Hospital Boston and a Pediatric Hematology/Oncology fellowship at the Children's Hospital Boston/Dana-Farber Cancer Institute where she also served as the Chief Fellow. Dr. Stegmaier is an Assistant Professor in the Department of Pediatrics at Harvard Medical School, an independent investigator in Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), and an attending physician at the Children’s Hospital Boston (CHB) and DFCI. She is also an Associate Member of the Broad Institute of Harvard and MIT.

Dr. Stegmaier has been the recipient of an American Society of Hematology Fellow Scholar Award, Hood Foundation Child Health Research Grant, Sidney Kimmel Cancer Foundation Scholar Award, Smith Family New Investigator Award and HHMI Physician-Scientist Early Career Award. She was recently named a Stand-Up-to-Cancer Innovative Research Grant Recipient and received a number of other awards, including, the ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement (2006), the 2007 Genome Technology “Tomorrow’s Principal Investigator” Award and the Society for Pediatric Research Young Investigator Award (2012). Outside of her scientific and clinical endeavors, Dr. Stegmaier has a passion for ballet and has performed professionally with Ballet Theater of Boston and the Cambridge Chamber Ballet.

LIke ThisLIke ThisLIke This


Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top research centers in the world for pediatric cancers and blood diseases. It brings together laboratory scientists and clinical researchers from Dana-Farber Cancer Institute and Boston Children’s Hospital in a single program. We investigate pediatric cancers and non-malignant blood disorders from every angle—from examining cells under the microscope to tracking the effectiveness of current drug regimens using the most advanced molecular methods—so that we can create better treatments for children seen here and around the world.

Learn more